STOCK TITAN
  1. Home
  2. Sec-filings
  3. SAVA
  4. [Form 4] Cassava Sciences, Inc. Insider Trading Activity

[Form 4] Cassava Sciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SAVA logo
Cassava Sciences

NASDAQ:SAVA

SAVA Rankings

#6217 Ranked by Market Cap
N/A Ranked by Dividends

SAVA Latest News

Jun 30, 2025
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
May 8, 2025
Cassava Reports Q1 2025 Financials Results, Provides Business Update
May 1, 2025
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Apr 21, 2025
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
Mar 25, 2025
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

SAVA Latest SEC Filings

Jun 30, 2025
[8-K] Cassava Sciences, Inc. Reports Material Event

SAVA Stock Data

104.35M
42.13M
12.57%
36.28%
29.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN